Compare $GTHP vs $RDGL | Chartloom

Compare

$GTHP vs $RDGL

Guided Therapeutics Inc · Vivos Inc

GTHP

Guided Therapeutics Inc

RDGL

Vivos Inc

Compare $GTHP vs $RDGL

Comparing Guided Therapeutics Inc and Vivos Inc

GTHPGuided Therapeutics Inc

RDGLVivos Inc

GTHPGuided Therapeutics Inc

Market cap

$19M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

450.8%

YTD performance

-63.0%

52W performance

-20.0%

FCF yield

-7.8%

RDGLVivos Inc

Market cap

$23M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

91.5%

YTD performance

-33.0%

52W performance

-45.9%

FCF yield

-11.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GTHP

RDGL

Detailed metrics comparison

GTHP

Guided Therapeutics Inc

RDGL

Vivos Inc

Market Cap

GTHP$19M

RDGL$23M

Enterprise Value

GTHP$21M

RDGL$20M

Price

GTHP$0.20

RDGL$0.05

P/E Ratio

GTHPN/A

RDGLN/A

P/S Ratio

GTHP29.70x

RDGL228.52x

EV/Sales

GTHP32.92x

RDGL204.98x

EV/EBITDA

GTHP0.00x

RDGL8.01x

P/B Ratio

GTHP33.42x

RDGL8.70x

P/FCF Ratio

GTHPN/A

RDGLN/A

EV/FCF

GTHP-14.21x

RDGL-8.08x

PEG Ratio

GTHPN/A

RDGLN/A

Forward P/E (NTM)

GTHPN/A

RDGLN/A

Forward P/S (NTM)

GTHPN/A

RDGLN/A

Revenue (TTM)

GTHP$650K

RDGL$99K

Revenue Growth (YoY)

GTHP450.8%

RDGL91.5%

Forward Rev Growth

GTHP0.0%

RDGL0.0%

Gross Margin (TTM)

GTHP75.8%

RDGL-25.8%

Operating Margin (TTM)

GTHP0.0%

RDGL0.0%

EBITDA Margin (TTM)

GTHP-336.2%

RDGL-2303.3%

Net Margin (TTM)

GTHP-560.6%

RDGL-3629.9%

FCF Margin (TTM)

GTHP-231.7%

RDGL-2536.8%

Net Income (TTM)

GTHP$-4M

RDGL$-4M

FCF (TTM)

GTHP$-2M

RDGL$-3M

EPS (TTM)

GTHP-$0.04

RDGL-$0.01

ROE (TTM)

GTHP-47148.0%

RDGL-15494.0%

ROA (TTM)

GTHP-24393.0%

RDGL-14414.0%

ROIC (TTM)

GTHP-37126.0%

RDGL-15494.0%

Cash

GTHP$12K

RDGL$2M

Debt

GTHP$2M

RDGL$0

Net Cash/Debt

GTHP$-2M

RDGL$2M

Current Ratio (TTM)

GTHP0.09x

RDGL48.85x

Quick Ratio (TTM)

GTHP0.00x

RDGL47.06x

Debt/Equity (TTM)

GTHP0.60x

RDGL0.00x

Debt/Assets (TTM)

GTHP0.0%

RDGL0.0%

Interest Coverage (TTM)

GTHPN/A

RDGLN/A

Net Debt/EBITDA (TTM)

GTHP0.00x

RDGL0.00x

Beta

GTHP0.69

RDGL-0.51

52W Performance

GTHP-20.0%

RDGL-45.9%

YTD Performance

GTHP-63.0%

RDGL-33.0%

% from 52W High

GTHP-63.0%

RDGL-63.1%

% from 52W Low

GTHP66.7%

RDGL17.4%

Asset Turnover (TTM)

GTHP0.73x

RDGL0.04x

FCF Yield (TTM)

GTHP-7.8%

RDGL-11.1%

Earnings Yield (TTM)

GTHP-18.9%

RDGL-15.9%

Dividend Yield (TTM)

GTHPN/A

RDGLN/A

Rule of 40

GTHP219.2

RDGL-2,445.3

EV/GP/RG

GTHPN/A

RDGLN/A

Ticker research

View GTHP research View RDGL research

Metric	GTHP Guided Therapeutics Inc	RDGL Vivos Inc
Market & Valuation
Market Cap	$19M	$23M
Enterprise Value	$21M	$20M
Price	$0.20	$0.05
P/E Ratio	N/A	N/A
P/S Ratio	29.70x	228.52x
EV/Sales	32.92x	204.98x
EV/EBITDA	0.00x	8.01x
P/B Ratio	33.42x	8.70x
P/FCF Ratio	N/A	N/A
EV/FCF	-14.21x	-8.08x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$650K	$99K
Revenue Growth (YoY)	450.8%	91.5%
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	75.8%	-25.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-336.2%	-2303.3%
Net Margin (TTM)	-560.6%	-3629.9%
FCF Margin (TTM)	-231.7%	-2536.8%
Net Income (TTM)	$-4M	$-4M
FCF (TTM)	$-2M	$-3M
EPS (TTM)	-$0.04	-$0.01
ROE (TTM)	-47148.0%	-15494.0%
ROA (TTM)	-24393.0%	-14414.0%
ROIC (TTM)	-37126.0%	-15494.0%
Financial Health
Cash	$12K	$2M
Debt	$2M	$0
Net Cash/Debt	$-2M	$2M
Current Ratio (TTM)	0.09x	48.85x
Quick Ratio (TTM)	0.00x	47.06x
Debt/Equity (TTM)	0.60x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.69	-0.51
52W Performance	-20.0%	-45.9%
YTD Performance	-63.0%	-33.0%
% from 52W High	-63.0%	-63.1%
% from 52W Low	66.7%	17.4%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.04x
FCF Yield (TTM)	-7.8%	-11.1%
Earnings Yield (TTM)	-18.9%	-15.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	219.2	-2,445.3
EV/GP/RG	N/A	N/A
Ticker research	View GTHP research	View RDGL research

Valuation

P/S Ratio

GTHP

29.70x

RDGL

228.52x

EV/FCF

GTHP

-14.21x

RDGL

-8.08x

Growth & revenue

Revenue Growth TTM

GTHP

450.8%

RDGL

91.5%

Forward Revenue Growth

GTHP

0.0%

RDGL

0.0%

Profitability & performance

Gross Margin

GTHP

75.8%

RDGL

-25.8%

ROE

RDGL

-15494.0%

GTHP

-47148.0%

FCF Yield %

GTHP

-7.8%

RDGL

-11.1%

52-Week Performance

GTHP

-20.0%

RDGL

-45.9%

Detailed metrics comparison

GTHP

Guided Therapeutics Inc

RDGL

Vivos Inc

Market Cap

GTHP$19M

RDGL$23M

Enterprise Value

GTHP$21M

RDGL$20M

Price

GTHP$0.20

RDGL$0.05

P/E Ratio

GTHPN/A

RDGLN/A

P/S Ratio

GTHP29.70x

RDGL228.52x

EV/Sales

GTHP32.92x

RDGL204.98x

EV/EBITDA

GTHP0.00x

RDGL8.01x

P/B Ratio

GTHP33.42x

RDGL8.70x

P/FCF Ratio

GTHPN/A

RDGLN/A

EV/FCF

GTHP-14.21x

RDGL-8.08x

PEG Ratio

GTHPN/A

RDGLN/A

Forward P/E (NTM)

GTHPN/A

RDGLN/A

Forward P/S (NTM)

GTHPN/A

RDGLN/A

Revenue (TTM)

GTHP$650K

RDGL$99K

Revenue Growth (YoY)

GTHP450.8%

RDGL91.5%

Forward Rev Growth

GTHP0.0%

RDGL0.0%

Gross Margin (TTM)

GTHP75.8%

RDGL-25.8%

Operating Margin (TTM)

GTHP0.0%

RDGL0.0%

EBITDA Margin (TTM)

GTHP-336.2%

RDGL-2303.3%

Net Margin (TTM)

GTHP-560.6%

RDGL-3629.9%

FCF Margin (TTM)

GTHP-231.7%

RDGL-2536.8%

Net Income (TTM)

GTHP$-4M

RDGL$-4M

FCF (TTM)

GTHP$-2M

RDGL$-3M

EPS (TTM)

GTHP-$0.04

RDGL-$0.01

ROE (TTM)

GTHP-47148.0%

RDGL-15494.0%

ROA (TTM)

GTHP-24393.0%

RDGL-14414.0%

ROIC (TTM)

GTHP-37126.0%

RDGL-15494.0%

Cash

GTHP$12K

RDGL$2M

Debt

GTHP$2M

RDGL$0

Net Cash/Debt

GTHP$-2M

RDGL$2M

Current Ratio (TTM)

GTHP0.09x

RDGL48.85x

Quick Ratio (TTM)

GTHP0.00x

RDGL47.06x

Debt/Equity (TTM)

GTHP0.60x

RDGL0.00x

Debt/Assets (TTM)

GTHP0.0%

RDGL0.0%

Interest Coverage (TTM)

GTHPN/A

RDGLN/A

Net Debt/EBITDA (TTM)

GTHP0.00x

RDGL0.00x

Beta

GTHP0.69

RDGL-0.51

52W Performance

GTHP-20.0%

RDGL-45.9%

YTD Performance

GTHP-63.0%

RDGL-33.0%

% from 52W High

GTHP-63.0%

RDGL-63.1%

% from 52W Low

GTHP66.7%

RDGL17.4%

Asset Turnover (TTM)

GTHP0.73x

RDGL0.04x

FCF Yield (TTM)

GTHP-7.8%

RDGL-11.1%

Earnings Yield (TTM)

GTHP-18.9%

RDGL-15.9%

Dividend Yield (TTM)

GTHPN/A

RDGLN/A

Rule of 40

GTHP219.2

RDGL-2,445.3

EV/GP/RG

GTHPN/A

RDGLN/A

Ticker research

View GTHP research View RDGL research

Metric	GTHP Guided Therapeutics Inc	RDGL Vivos Inc
Market & Valuation
Market Cap	$19M	$23M
Enterprise Value	$21M	$20M
Price	$0.20	$0.05
P/E Ratio	N/A	N/A
P/S Ratio	29.70x	228.52x
EV/Sales	32.92x	204.98x
EV/EBITDA	0.00x	8.01x
P/B Ratio	33.42x	8.70x
P/FCF Ratio	N/A	N/A
EV/FCF	-14.21x	-8.08x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$650K	$99K
Revenue Growth (YoY)	450.8%	91.5%
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	75.8%	-25.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-336.2%	-2303.3%
Net Margin (TTM)	-560.6%	-3629.9%
FCF Margin (TTM)	-231.7%	-2536.8%
Net Income (TTM)	$-4M	$-4M
FCF (TTM)	$-2M	$-3M
EPS (TTM)	-$0.04	-$0.01
ROE (TTM)	-47148.0%	-15494.0%
ROA (TTM)	-24393.0%	-14414.0%
ROIC (TTM)	-37126.0%	-15494.0%
Financial Health
Cash	$12K	$2M
Debt	$2M	$0
Net Cash/Debt	$-2M	$2M
Current Ratio (TTM)	0.09x	48.85x
Quick Ratio (TTM)	0.00x	47.06x
Debt/Equity (TTM)	0.60x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.69	-0.51
52W Performance	-20.0%	-45.9%
YTD Performance	-63.0%	-33.0%
% from 52W High	-63.0%	-63.1%
% from 52W Low	66.7%	17.4%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.04x
FCF Yield (TTM)	-7.8%	-11.1%
Earnings Yield (TTM)	-18.9%	-15.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	219.2	-2,445.3
EV/GP/RG	N/A	N/A
Ticker research	View GTHP research	View RDGL research